Search Results

Keywords: synthetic

Will GW’s multibillion-dollar sale ‘open floodgates’ to pharma-cannabis deal-making?

February 5, 2021 · Updated April 7, 2021

Jazz Pharmaceuticals’ planned $7.2 billion takeover of United Kingdom-based GW Pharmaceuticals could kick off a wave of deal-making between pharma and medical cannabis companies, analysts and industry sources say. But rather than all cannabis producers benefiting, only businesses that have marketable intellectual property and an established foothold in the medical cannabinoid arena will draw serious […]

Read More

Injectable cannabis overdose drug to be developed by Irisys

January 19, 2021 · Updated October 13, 2021

Cannabis-related emergency department visits are thought to have more than tripled between 2011 and 2019, coincident with the legalization of recreational and medical cannabis in many US states. Yet there are no approved drugs to treat overdoses due to cannabis or synthetic cannabinoids like Spice and K2. Irisys, a contract development and manufacturing organization based […]

Read More

Study provides clues about how minor cannabinoids work in the body

December 14, 2020 · Updated October 13, 2021

We’re learning a lot about the ways THC and CBD interact with the endocannabinoid system (ECS) to stimulate appetite and help treat pain, anxiety, and epileptic seizures. But cannabis contains a vast array of minor cannabinoids as well. What is their therapeutic potential and how do they work in the body? These are questions that […]

Read More

Biomedican successfully biosynthesizes two rare cannabinoids

December 14, 2020 · Updated October 13, 2021

A California life sciences company named Biomedican is drawing significant attention for the rapid progress it’s made in patented, low-cost methods of biosynthesizing rare cannabinoids. The company uses a proprietary strain of yeast named Yarrowia lipolytica to extract pharmaceutical-grade cannabinoids that are chemically identical to those extracted from cannabis plants. Aside from producing these cannabinoids […]

Read More

Epidiolex maker GW Pharma reports record quarterly revenue of $137 million

November 4, 2020

United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales of its cannabidiol medicine Epidiolex. GW’s total revenue for the third quarter reached $137.1 million, about 16% more than the previous quarter’s $121.3 million. Epidiolex sales in the United States accounted for 87% of the company’s overall […]

Read More

Newly enforced law might harm Italy’s medical cannabis market, pharmacies warn

October 23, 2020

Italian regulators have reminded pharmacies they are barred from shipping medical cannabis preparations to customers, a major departure from how patients have accessed the medicine for years in the southern European country. Business and patient groups warn that a government crackdown on such shipments – based on a 30-year-old law – could turn back the […]

Read More

Australia sees 5,000 cannabis patient approvals for second straight month

September 11, 2020

Roughly 5,270 patients were approved for medical cannabis treatment in Australia in August via the SAS Category B pathway, the second month in a row the country recorded more than 5,000 individual approvals. The August figure represents a 5% drop from the previous month. But the number is more than 17% higher than the average […]

Read More

Ottawa, Canada, firm gains FDA approval to test potential COVID-19 drug

September 10, 2020 · Updated October 13, 2021

On the heels of promising mice-based research that indicated THC might provide effective protection from acute respiratory distress syndrome (ARDS), Ottawa, Canada-based Tetra Bio-Pharma has received FDA approval for Phase 1 testing of its synthetic, THC-free, cannabinoid drug, ARDS-003. ARDS is a severe lung injury that leads to significant morbidity and mortality, especially in older […]

Read More

Global Retreat: Canadian cannabis firms pull back global aspirations

September 1, 2020 · Updated June 6, 2021

Back in the early days of Canada’s regulated adult-use cannabis industry, some of the country’s biggest publicly traded marijuana producers discovered that investors rewarded international ambitions. The domestic recreational marijuana market that launched in October 2018 was exciting, of course, but that opportunity would always be limited by Canada’s relatively small population of around 38 […]

Read More

Vancouver biotech company produces CBG from yeast

August 26, 2020

It wasn’t long ago that cannabis experts thought it unlikely anyone could produce cannabinoids in quantity through biosynthesis, using genetically engineered yeast or bacteria. But, now, Willow Biosciences—an 18-month-old company based in Vancouver—has started a pilot production run of 500 liters (132 gallons) of cannabigerol, or CBG. Plans are to deliver the first samples of […]

Read More

Incorrect storage of CBD extracts could affect THC levels

July 23, 2020 · Updated October 13, 2021

Research published in Cannabis and Cannabinoid Research suggests the way CBD extracts are stored could have an effect on how much THC the final product contains. It was already known that, when CBD is stored in an acidic environment, some of it can cyclize to form THC. If the amount of THC impurities in stored […]

Read More